Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer

Epigenomics

Volumn 9, Issue 6, 2017, Pages 849-862

  He, Tao ^a,b   Zhang, Meiying ^a,c   Zheng, Ruipan ^a,d   Zheng, Shufang ^b   Linghu, Enqiang ^a   Herman, James G ^c   Guo, Mingzhou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c NANKAI UNIVERSITY   (China)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

cisplatin; colorectal cancer; DNA damage repair; epigenetics; methylation; SLFN11

Indexed keywords

B RAF KINASE; CISPLATIN; CYCLIN D1; CYCLIN E; CYCLIN E1; DNA HELICASE; K RAS PROTEIN; MUTL PROTEIN HOMOLOG 1; RNA HELICASE; SCHLAFEN 11; SOMATOMEDIN B; TRANSCRIPTION FACTOR RUNX3; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NUCLEAR PROTEIN; SLFN11 PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GROUPS BY AGE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; COLORECTAL TUMOR; DRUG RESISTANCE; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELLS, CULTURED; CISPLATIN; COLORECTAL NEOPLASMS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC;

EID: 85020775070     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi-2017-0019     Document Type: Article

References (26)

1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359-E386 (2015).
2. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J. Clin. 59(6), 366-378 (2009).
3. Armaghany T, Wilson JD. Chu Q, et al. Geneticalterations in colorectal cancer. Gastrointestinal cancer research. 5(1), 19-27( 2012).
4. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135(4), 1079-1099 (2008).
5. Nyberg KA, Michelson RJ, CW P, Weinert TA. Toward maintaining the genome: DNA damage and replication checkpoints. Annu. Rev. Genet. 36(1), 617 (2002).
6. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 138(6), 2044-2058 (2010).
7. Gao D, Herman JG, Guo M. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. Oncotarget 7(24), 37331-37346 (2016).
8. Schwarz DA, Katayama CD, Hedrick SM. Schlafen, a new family of growth regulatory genes that affect thymocyte development. Immunity 9(5), 657-668 (1998).
9. Bustos O, Naik S, Ayers G et al. Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence. Gene 447(1), 1-11 (2009).
10. Mavrommatis E, Fish EN, Platanias LC. The Schlafen family of proteins and their regulation by interferons. J. Interferon Cytokine Res. 33(4), 206-210 (2013).
11. De La Casa-Esperon E. From mammals to viruses: the Schlafen genes in developmental, proliferative and immune processes. Biomol. Concepts 2(3), 159-169 (2011).
12. The Cancer Genome ATLAS. http://cancergenome.nih.gov
13. Zoppoli G, Regairaz M, Leo E et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc. Natl Acad. Sci. USA 109(37), 15030-15035 (2012).
14. Nogales V, Reinhold WC, Varma S et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget 7(3), 3084-3097 (2016).
15. Flejou JF. [WHO Classification of digestive tumors: the fourth edition]. Ann. Pathol. 31(Suppl. 5), S27-S31 (2011).
16. Morandi L. WO2011104695 A2 (2011).
17. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellitestable colon cancers. Cancer Res. 65(14), 6063 (2005).
18. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93(18), 9821-9826 (1996).
19. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large populationbased sample. J. Mol. Diagn. 9(3), 305-314 (2007).
20. Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Cancer Res. 73(23), 7101-7110 (2013).
21. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem. Pharmacol. 79(10), 1398 (2010).
22. Tian L, Song S, Liu X et al. Schlafen-11 platinum drugssensitizes colorectal carcinoma cells toirinotecan Anticancer Drugs 25(10), 1175-1181 (2014).
23. Bartkova J, Horejsí Z, Koed K et al. DNA irinotecan damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7035), 864-870 (2005).
24. Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity tumorigenesis of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105(44), 17079-17084 (2008).
25. Zaanan A, Cuilliere-Dartigues P, Guilloux A et al. Impact of p53 expression and microsatellite instability on stage III colon cancerdisease-free survival in patients treated by 5-fluorouracil and leucovorin withor without oxaliplatin. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 21(4), 772-780 (2010).
26. Mu Y, Lou J, Srivastava M et al. SLFN11 inhibits checkpoint maintenance and homologous recombination repair. EMBO Rep. 17(1), 94-109 (2016).